NCT05783804 Plaque Reversal With Early, Aggressive Lipid Lowering Therapy
| NCT ID | NCT05783804 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Condition | Coronary Artery Disease Progression |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-07-07 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2022-07-07 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with heterozygous familial hypercholesterolemia * Adult between 18 and 50 years old * LDL cholesterol levels above 100 mg/dl (\>2.6 mmol/L) at inclusion Exclusion Criteria: * Renal insufficiency, defined as eGFR \< 30 ml/min * History of atherosclerotic cardiovascular events * Atrial fibrillation * Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
Contact & Investigator
Erik SG Stroes, MD, PhD
PRINCIPAL INVESTIGATOR
Amsterdam UMC, location AMC
Frequently Asked Questions
Who can join the NCT05783804 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Coronary Artery Disease Progression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05783804 currently recruiting?
Yes, NCT05783804 is actively recruiting participants. Contact the research team at e.s.stroes@amsterdamumc.nl for enrollment information.
Where is the NCT05783804 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands.
Who is sponsoring the NCT05783804 clinical trial?
NCT05783804 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The principal investigator is Erik SG Stroes, MD, PhD at Amsterdam UMC, location AMC. The trial plans to enroll 60 participants.